Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $13.8 million.

  • Amphastar Pharmaceuticals' Change in Receivables rose 7121.04% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year decrease of 6733.21%. This contributed to the annual value of $21.7 million for FY2024, which is 1692.48% down from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Change in Receivables stood at $13.8 million for Q3 2025, which was up 7121.04% from -$12.3 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' 5-year Change in Receivables high stood at $23.2 million for Q1 2024, and its period low was -$12.3 million during Q2 2025.
  • In the last 5 years, Amphastar Pharmaceuticals' Change in Receivables had a median value of $7.8 million in 2022 and averaged $4.3 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first surged by 143046.36% in 2022, then tumbled by 42882.03% in 2024.
  • Quarter analysis of 5 years shows Amphastar Pharmaceuticals' Change in Receivables stood at $755000.0 in 2021, then soared by 1430.46% to $11.6 million in 2022, then tumbled by 135.39% to -$4.1 million in 2023, then increased by 28.93% to -$2.9 million in 2024, then skyrocketed by 574.57% to $13.8 million in 2025.
  • Its Change in Receivables was $13.8 million in Q3 2025, compared to -$12.3 million in Q2 2025 and $8.1 million in Q1 2025.